Evidence map›Paper›PMID 37816905›Full record

ArticleLangenbeck's archives of surgery2023

Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review.

Milton Mui, Molly Clark, Tamara M S H Vu, Nicholas Clemons, Frédéric Hollande, Sara Roth, Robert Ramsay, Michael Michael, Alexander G Heriot, Joseph C H Kong

Open access · hybridAbstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in Langenbeck's archives of surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Milton MuiDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. milton.mui@petermac.org.ORCID http://orcid.org/0000-0002-1507-8228
Molly ClarkDepartment of Colorectal Surgery, Alfred Hospital, Melbourne, Victoria, Australia.
Tamara M S H VuDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Nicholas ClemonsSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Frédéric HollandeDepartment of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia.
Sara RothSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Robert RamsaySir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Michael MichaelSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Alexander G HeriotDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Joseph C H KongDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
The University of Melbourne · AUPeter MacCallum Cancer Centre · AUThe Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWhilst the treatment paradigm for colorectal cancer has evolved significantly over time, there is still a lack of reliable biomarkers of treatment response. Treatment decisions are based on high-risk features such as advanced TNM stage and histology. The role of the tumour microenvironment, which can influence tumour progression and treatment response, has generated considerable interest. Patient-derived explant cultures allow preservation of native tissue architecture and tumour microenvironment. The aim of the scoping review is to evaluate the utility of patient-derived explant cultures as a preclinical model in colorectal cancer.

methodsA search was conducted using Ovid MEDLINE, EMBASE, Web of Science, and Cochrane databases from start of database records to September 1, 2022. We included all peer-reviewed human studies in English language which used patient-derived explants as a preclinical model in primary colorectal cancer. Eligible studies were grouped into the following categories: assessing model feasibility; exploring tumour microenvironment; assessing ex vivo drug responses; discovering and validating biomarkers.

resultsA total of 60 studies were eligible. Fourteen studies demonstrated feasibility of using patient-derived explants as a preclinical model. Ten studies explored the tumour microenvironment. Thirty-eight studies assessed ex vivo drug responses of chemotherapy agents and targeted therapies. Twenty-four studies identified potential biomarkers of treatment response.

conclusionsGiven the preservation of tumour microenvironment and tumour heterogeneity, patient-derived explants has the potential to identify reliable biomarkers, treatment resistance mechanisms, and novel therapeutic agents. Further validation studies are required to characterise, refine and standardise this preclinical model before it can become a part of precision medicine in colorectal cancer.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsBiomarkersHumansPrecision MedicineTumor MicroenvironmentAntineoplastic AgentsBiomarkersColorectal cancerPatient-derived explantsPrecision medicineTumour microenvironment

Identifiers

PMID37816905
PMCPMC10564805
OpenAlexW4387493675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.